Loading...
Loading...
Gevo, Inc.
GEVO commented on the lawsuit filed today by Butamax™ Advanced Biofuels, LLC (Butamax) alleging infringement of U.S. Patent No. 8,178,328 (‘328 Patent).
“The claims in the ‘328 Patent are virtually identical to the claims in Butamax's earlier-issued 7,851,188 Patent (‘188 Patent) which were recently rejected and declared unpatentable by the U.S. Patent and Trademark Office during reexamination,” said Brett Lund, Gevo's Executive Vice President and General Counsel. “The ‘328 Patent issued from a child application of the ‘188 Patent and purports to cover engineered isobutanol-producing microorganisms.”
“Like Butamax's ‘188 Patent, the technology described in the ‘328 Patent was invented by others and repeatedly described in journal publications dating back to the 1960s,” continued Lund. “We will request reexamination of the ‘328 Patent using similar arguments and are extremely confident that the outcome will be the same.”
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in